Basaloid squamous cell carcinoma is a variant of squamous cell carcinoma. This malignancy has a predilection fo r the upper aerodiges tive tract, although it has been fo und in multiple other sites. The tumor is highly aggressive biologically, and the overall prognosis is poor despite intensive treatment. We describe a case ofbasaloid squamous cell carcinoma ofthe larynx that metastasized to the spine.
Introduction
Various types of tumors affect the upper aerod igestive tract, the most common of which is squamous cell carcinoma . Squ amou s cell carcinoma itself has many variants, includ ing the bimo rphic variant basaloid squamous cell carcinom a. I Th ese neoplasms have been found in multiple sites in the body-including the anus, cervix, and lun gs-but they hav e a predil ect ion for the upp er aerodiges tive tract. The most comm on of these sites are the suprag lottic laryn x, hypophary nx, and base of the tongue.' Other sites includ e the floor ofthe mouth , tonsils, nasal cavity, paranasal sinuses, nasopharynx, palate, buccal mucosa, esophag us, and trachea.' In this article , we report the case of a patient with basaloid squamous cell carcinoma of the larynx that metastasized to the spine.
Case report A 48-ye ar-old man was referre d to our outpatient department for evaluation of a 2-month history of progressive hoarseness that was associated with cough and expectoration of mucoid sputum. He was a chronic cigarette smoker.
Indire ct laryngoscopy detected the presence of an ulceroexophyt ic gro wth that involved the right true vocal fold , right false vocal fold , right aryepiglotti c fold, and right arytenoid with fixity of the right hemilarynx. The From remainder of the laryn x and the pharynx were normal, and there were no palp able neck nodes. After a routine blood and urine examination, direct laryngoph aryngoscopy was performed under local anesthesia to assess the extent of the lesion , and these findings confirmed those found on indirect laryngoscopy. A biopsy speci me n was taken and sent for histopathologi c exa mination, which identified the mass as a basalo id squamous cell carc inoma. The tumor was made up of small-to-medium-sized cells that featured hyperchromati c nuclei and scant cytoplasm (figure 1). The cell s were arra nged in lobul es in a trabecular pattern . There were areas of comedo-type necrosis, adeno id cys tic pattern, and extensive necro sis. The patient underw ent a rightsided, vertical partial hemil aryngectom y. His postop erative period was uneventful , and oral feedin g resumed on postoperative day 10.
On postoperative day 12, the patient complained of back pain, which radiated to the upper abdome n and was aggra vated by stra ining and movement. Phy sical exa mination of his back rev ealed tenderness over the TIl vertebra, but no motor or sensory deficit s in the lower limb s. An x-ray of the thoracolumbar spin e showed that TIl had coll apsed and was destroy ed (figure 2). The patient experienced a progressive worsening of his pain, and he began to notice weakness in his right lower limb. The results of liver fun ction tests and ultrasound scan ning ofthe abdomen were within norm al limits. Findings on xray of the chest and the rest of the bony skeleton were also normal. After consultation with an orthopedic surgeon, we made a prelim inary clini cal diagno sis of tub erculosis of the spine. To confirm the diagno sis, we obtained a fineneedle aspiration biops y spec imen, guided by computed tom ography (CT) , from TI l ( figure 3 ). An alysis of the spinal specimen reve aled that it represented a met astasis of the laryngeal basalo id squamous cell carcinoma.
The patient was fitted with a spinal brace and referred for radiotherapy. He was irradiated with 3,800 cGy to T 11 (800 cGy in one fraction followed by 3,000 cGy in 10 fractions) and with 4,500 cGy to the prim ary site (in 15 fractions). Following radiotherapy, the pati ent' s back 
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DOSAGE AND ADMINISTRATION
Discussion
The term basaloid squamous cell carcinoma was first used by Wain et al in their 1986 report of 10 cases that had occurred in the tongue, hypopharynx, and larynx ." Thi s malignancy generally affect s elderly men who are smokers and/or alcoho lics.' In a series of cases reported by Ferlito et ai, the average age of patients at their initia l evaluation was 63.33 years.' At 48 years of age, our patient was relatively young.
Clinically, basaloid squamous cell carcinoma is a highly aggres sive tumor. It is char acteri zed by a high incidence of early reg ional and distant metastasis to the lung s, liver, bones, brain, and skin.' Another peculiarity in our patient was the metastasis to the spine, even though the region al lymph nodes were uninvolv ed. In light of this development, the absence of metastasis to the cervical lymph nodes cann ot be considered to be a favorable progno stic sign because the tumor might have already spread to distant sites. Therefore, an extensive work-up-including whole -body CT-is mandatory in all cases ofbasaloid squamous cell carcinoma.
Histopathologically, the tumor is most likely to be confu sed with adenoid cystic carc inoma and small-cell undifferenti ated carcinoma. Differentiation can be made on clinical , histologic, and immunohistochemical grounds.' By the time they are evalu ated , most of these patients are alread y at an advanced stage-usually stage III or IV. Our patient was at stage III and had alre ady developed a distant metastasis, which demonstrates the aggres sive nature of this tumor.
Tre atment consi sts of radical surgery, radiotherapy , or both, with or without chemotherapy; adjuvant chemotherapy might have a role in patient s with meta stasis.' 
